



Published in final edited form as:

*Nat Immunol.* 2019 May ; 20(5): 534–545. doi:10.1038/s41590-019-0367-4.

## IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival

Saikat Majumder<sup>1</sup>, Nilesh Amatya<sup>1</sup>, Shankar Revu<sup>1</sup>, Chetan V Jawale<sup>1</sup>, Dongwen Wu<sup>1</sup>, Natalie Rittenhouse<sup>2</sup>, Ashley Menk<sup>3</sup>, Saran Kumpul<sup>1</sup>, Fang Du<sup>1</sup>, Itay Raphael<sup>1</sup>, Amrita Bhattacharjee<sup>2</sup>, Ulrich Siebenlist<sup>4</sup>, Timothy W Hand<sup>2</sup>, Greg M Delgoffe<sup>3</sup>, Amanda C Poholek<sup>2</sup>, Sarah L Gaffen<sup>1</sup>, Partha S Biswas<sup>1</sup>, and Mandy J McGeachy<sup>1,5</sup>

<sup>1</sup>Department of Medicine, University of Pittsburgh, Pittsburgh PA, USA

<sup>2</sup>Department of Pediatrics, University of Pittsburgh, Pittsburgh PA, USA

<sup>3</sup>Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh PA, USA

<sup>4</sup>Immune Activation Section, NIAID, National Institutes of Health, Bethesda MD, USA

### Abstract

Lymph node (LN) stromal cell populations expand during the inflammation that accompanies T cell activation. Interleukin 17 (IL-17)-producing T helper (T<sub>H</sub>17) cells promote inflammation through induction of cytokines and chemokines in peripheral tissues. We demonstrate a critical requirement for IL-17 in the proliferation of lymph node (LN) and spleen stromal cells, particularly fibroblastic reticular cells (FRCs), during experimental autoimmune encephalomyelitis and colitis. Without IL-17 receptor signaling, activated FRCs underwent cell cycle arrest and ultimately apoptosis, accompanied by signs of nutrient stress *in vivo*. IL-17 signaling in FRCs was not required for T<sub>H</sub>17 cell development, but failed FRC proliferation impaired germinal center formation and antigen-specific antibody production. IL-17 induction of the transcriptional coactivator I $\kappa$ B $\zeta$  mediated increased glucose uptake and mitochondrial *Cpt1a* expression. Hence, IL-17 produced by locally differentiating T<sub>H</sub>17 cells is an important driver of inflamed LN stromal cell activation, through metabolic reprogramming required to support proliferation and survival.

<sup>5</sup>Corresponding author: mandymcgeachy@pitt.edu.

#### AUTHOR CONTRIBUTIONS

S.M. and M.J.M. conceptualized and designed the study, performed analysis, and wrote the manuscript; S.M., N.A., S.R., C.V.J., P.S.B., D.W., A.M. performed experiments; N.R., I.R., N.A., A.C.P., S.K. performed or assisted with analysis; F.D., A.B., U.S., T.W.H., G.M.D., S.L.G., P.S.B., M.J.M. assisted with methodology, resources and analysis of experiments; T.W.H., A.P., P.S.B., M.J.M. reviewed and edited the manuscript.

#### ACCESSION NUMBERS

GEO accession number GSE124649 for RNA sequencing data.

#### COMPETING INTERESTS STATEMENT

The authors declare no competing interests

#### DATA AVAILABILITY

The RNA-Sequencing datasets generated for Figure 6 and 7 are available at GEO accession number GSE124649. All other data used to generate figures for the study are available upon request by the corresponding author

## INTRODUCTION

$T_H17$  cells promote pathology in a variety of autoimmune conditions, and therapies targeting  $T_H17$  cells are proving highly effective in some autoimmune diseases<sup>1, 2</sup>. Interleukin 17 (IL-17), the prototypical  $T_H17$  cytokine, targets non-hematopoietic cells to induce production of chemokines that attract myeloid cells, pro-inflammatory cytokines such as IL-6, and antimicrobial peptides<sup>2</sup>.  $T_H17$  cells are therefore important regulators of extracellular bacterial and fungal pathogens. In the healthy skin and gut, IL-17 maintains microbial homeostasis without overt inflammation, and supports gut epithelial healing following toxic injury<sup>3, 4</sup>. IL-17 also promotes development of tertiary lymphoid structures that support protective immunity, but may perpetuate chronic inflammation during autoimmunity<sup>5, 6</sup>. Hence, the context of IL-17 signaling plays an important role in eliciting an inflammatory or tissue-protective response.

Like all naïve T cells,  $T_H17$  cells are activated and differentiate in secondary lymphoid organs (SLOs) including lymph nodes (LNs) and spleen, where they have an opportunity to interact with resident stromal cells during differentiation. Fibroblastic reticular cells (FRCs) are the critical non-hematopoietic stromal cells in SLOs. T cell zone FRCs were the first identified FRC population, characterized to express the chemokine CCL19 and IL-7 to attract T cells and support their survival<sup>7</sup>. They also secrete extracellular matrix (ECM) that ensheathes conduits carrying lymph for dendritic cell (DC) sampling, and forms a cellular scaffold that facilitates T cell migration<sup>7</sup>. In addition to T cell zone stroma, FRCs are now known to comprise heterogeneous subpopulations occupying distinct niches throughout the LN. Recent single-cell level analyses of LN stromal cells delineated seven podoplanin (PDPN)<sup>+</sup> FRC subpopulations<sup>8</sup>. These subsets include follicular dendritic cells (FDCs) in B cell follicles, marginal zone reticular cells (MRCs) in the subcapsular sinus, 2 populations of medullary reticular cells (MedRCs) known to support plasma cells<sup>9</sup>, and 3 subsets of T zone reticular cells (TRCs): classical CCL19<sup>hi</sup> TRCs, a CXCL9<sup>+</sup> interfollicular TRC population, and a CCL19<sup>lo</sup> TRC population that expresses the B cell survival factor BAFF and the B cell-attracting chemokine CXCL13 at B:T zone borders<sup>10</sup>.

FRC depletion or dysfunction in mouse models causes SLO follicular disorganization, reduced T and B cell viability, and impaired antiviral immunity<sup>10, 11</sup>. Chronic fibrosis of LNs that occurs during HIV or SIV infection exacerbates T cell loss due to reduced access to IL-7 from FRCs coated in excess ECM<sup>12, 13</sup>. Similar LN fibrosis with reduced FRC numbers was found in subjects from Uganda with chronic immune activation syndrome, corresponding to reduced T cells and impaired antibody production following vaccination<sup>14</sup>. Conversely, FRCs regulate the magnitude of type 1 CD4<sup>+</sup> T helper ( $T_H1$ ) and CD8<sup>+</sup> T cell responses through production of nitric oxide in response to interferon- $\gamma$  (IFN- $\gamma$ )<sup>15, 16, 17</sup>. Similarly, FRCs regulate type 1 innate lymphoid cell (ILC1) responses by reducing IL-15 production in response to MyD88 signaling<sup>18</sup>. Thus FRCs are thought to reduce immunopathology during viral infection. By presenting self antigens, FRCs can delete self-reactive CD8<sup>+</sup> T cells and induce CD4<sup>+</sup> regulatory T (Treg) cells<sup>19, 20</sup>. Hence FRCs play important roles both in supporting and regulating adaptive immune responses.

Following pathogen invasion or immunization, activated DCs migrate to local LNs and trigger endothelial ‘shutdown’, generating rapid organ size increase due to retained lymphocytes<sup>21</sup>. At first, cytoskeletal relaxation in FRC allows stretching of the network<sup>22</sup>. Then, FRCs proliferate to provide the increased stromal support needed by the expanded lymphoid tissue<sup>23, 24</sup>. The kinetics of FRC proliferation are offset against LN size increase by several days<sup>24</sup> and more closely follow activation kinetics of T cells, which are thought to provide proliferation-supporting signals<sup>24, 25</sup>. However, the nature of these signals have been unclear. In this study, we investigated the role of IL-17 produced by differentiating T<sub>H</sub>17 cells on local FRCs during inflammation in SLOs.

## RESULTS

### T<sub>H</sub>17 cells drive increased ECM in inflamed LNs

Increased production of ECM components such as fibronectin and collagen are features of T<sub>H</sub>17-mediated inflammation, including the central nervous system (CNS) during multiple sclerosis (MS) or its animal model experimental autoimmune encephalomyelitis (EAE)<sup>26, 27</sup>. Following immunization with the myelin oligodendrocyte glycoprotein peptide MOG(aa35–55) in complete Freund’s adjuvant (CFA) to induce EAE, we observed that expression of *Fn1* (encoding fibronectin) increased along with *Il17a* in draining LNs (Supplementary Fig. 1a). Immunization-induced *Fn1* required IL-23R (Fig. 1a), implicating ‘type-17’ IL-23R<sup>+</sup> cells that could be T<sub>H</sub>17 cells, type 3 innate lymphoid cells (ILC3) or  $\gamma\delta$  T cells. We therefore dissected the role of de novo generated antigen-specific T<sub>H</sub>17 cells in driving *Fn1* expression following immunization. Wild-type or *Il23r*<sup>-/-</sup> CD4<sup>+</sup> TCR-transgenic OT-II cells were transferred into wild-type or *Il23r*<sup>-/-</sup> hosts, which were then immunized with the OT-II-activating ovalbumin peptide OVA(aa323–339) in CFA. As expected<sup>28</sup>, IL-17 was only strongly induced when OT-II cells expressed IL-23R (i.e. wild-type OT-II), and did not require host IL-23R (Fig. 1b). Similarly, *Fn1* expression was only increased when OT-II cells were able to successfully produce IL-17 (Fig. 1c).

To determine whether IL-17 itself was required for *Fn1* increases in inflamed LNs, we immunized *Il17a*<sup>-/-</sup> mice with MOG(35–55) in CFA. Indeed, *Fn1* expression was impaired in dLNs of *Il17a*<sup>-/-</sup> mice compared to wild-type following immunization (Fig. 1d). Immunization-elicited *Fn1* was dependent on IL-17RA and the signaling adaptor Act1, further confirming the requirement for the IL-17 signaling pathway (Fig. 1e, f). To confirm these gene expression changes resulted in protein changes, we performed immunofluorescence (IF) staining. Fibronectin expression again increased in wild-type but not *Il17ra*<sup>-/-</sup> dLNs following immunization (Fig. 1g). Expression of *Col1a1*, encoding collagen type 1a was also increased in dLNs in an IL-17RA-dependent manner following immunization (Fig. 1h), but *Col3a1* did not change indicating some specificity to the ECM components that were regulated by IL-17 (Supplementary Fig. 1b). Correspondingly, collagen deposition was increased in wild-type but not *Il17ra*<sup>-/-</sup> mouse dLNs (Fig 1I). Despite these defects in ECM, the gross appearance, mass and cell numbers were similar between dLNs from immunized *Il17ra*<sup>-/-</sup>, *Il17*<sup>-/-</sup> and wild-type controls (Fig 1J-L, Supplementary Fig. 1c). These data thus suggested that T<sub>H</sub>17 cells promote expression of

ECM in inflamed dLNs through IL-17 signaling, independently of LN size or hypercellularity.

### IL-17 signaling is required for FRC population expansion

FRCs are the major cell type that expresses fibronectin and type I collagen in LN<sup>7</sup>, and IF staining confirmed co-localized expression of the FRC marker ERTR7 with fibronectin in dLN (Supplementary Fig. 2a). We therefore analyzed the stromal cell composition of naïve LNs and inflamed dLNs from immunized wild-type and *Il17ra*<sup>-/-</sup> mice. CD45<sup>-</sup>CD31<sup>-</sup>PDPN<sup>+</sup> FRC were significantly increased in number in wild-type inflamed LN and spleen from immunized animals compared to naïve LN, and this increase required IL-17 signaling as dLN from immunized *Il17ra*<sup>-/-</sup> or *Il17*<sup>-/-</sup> had significantly reduced FRC numbers compared to wild-type (Fig. 2a, b and Supplementary Fig. 2b, c). As further confirmation of the importance of IL-17 signaling in inflamed LN, FRC numbers were reduced in absence of the IL-17R signaling adaptor Act1 (Fig 2c). Regnase-1 is a potent negative regulator of IL-17 signaling<sup>29</sup>, and accordingly mice with reduced Regnase-1 expression had increased numbers of FRCs following immunization (Fig 2d). In contrast, numbers of CD45<sup>-</sup>PDPN<sup>+</sup>CD31<sup>+</sup> lymphoid endothelial cells (LECs) and CD45<sup>-</sup>PDPN<sup>-</sup>CD31<sup>+</sup> blood endothelial cells (BECs) were not different in dLN from immunized *Il17ra*<sup>-/-</sup> compared to controls (Fig. 2e, f, Supplementary Fig. 2b). PDPN<sup>+</sup>CD21<sup>+</sup>CD35<sup>+</sup> follicular dendritic cells (FDC) and PDPN<sup>+</sup>MadCAM1<sup>+</sup> marginal zone reticular cells (MRC), were unchanged by IL-17 deficiency (Fig 2g,h). While not an exhaustive characterization of stromal cell subsets, these data suggested that the CD21<sup>-</sup>MadCAM1<sup>-</sup>CCL19<sup>+</sup> TRC population, which is also the largest and best positioned to interact with T<sub>H</sub>17 cells, may be a functional target of IL-17 signaling in lymphoid tissues.

### FRC respond directly to IL-17 during inflammation

We next sought to determine the factors that regulate IL-17-dependent increases in FRC numbers. Lymphotoxin (LT) $\alpha$  and LT $\beta$  are critical for development, expansion and maintenance of FRC populations in LN<sup>11</sup>. *Lta* and *Ltb* expression increased in response to immunization, but were not different between wild-type and *Il17ra*<sup>-/-</sup> mice, suggesting that IL-17 does not regulate lymphotoxin availability (Fig. 3a,b). FRC numbers in LN from naïve *Il17ra*<sup>-/-</sup> mice were similar to wild-type mice (Supplementary Fig. 3a), further supporting an IL-17-independent function of lymphotoxins in FRC development. To rule out any contribution of developmental defects to the impaired FRC response in *Il17*<sup>-/-</sup> mice, we immunized wild-type mice with MOG(35–55) in CFA and administered IL-17 neutralizing antibodies (Supplementary Fig. 3b). FRC numbers were again significantly reduced in LN from anti-IL-17 treated mice compared to isotype controls (Fig. 3c), despite similar LN size between these groups (Supplementary Fig. 3c). Moreover, *Fn1* expression was significantly reduced when IL-17 was neutralized (Supplementary Fig. 3d).

These data confirmed a role for IL-17 in promoting FRC proliferation in mature SLO following immunization. However, they did not rule out an indirect effect of IL-17 within the LN. For example, IL-17 signaling leads to neutrophil recruitment<sup>30</sup>, and accordingly neutrophils were decreased in immunized *Il17ra*<sup>-/-</sup> dLN compared to wild-type (Fig. 3d). To determine whether IL-17 signaling is required in FRC, FRC *Il17ra* mice were generated by

crossing *Il17ra*<sup>fl/fl</sup> mice with the FRC-specific CCL19<sup>Cre11, 22, 31</sup> (Supplementary Fig. 3e). *Ccl19*<sup>Cre</sup>*Il17ra*<sup>fl/+</sup> littermates were analyzed as controls (FRC<sup>ctrl</sup>). FRC *Il17ra* showed no defect in neutrophil recruitment following immunization (Fig. 3e), indicating that FRC are not a necessary source of neutrophil-attracting chemokines in response to IL-17 signaling in LN. As observed in *Il17ra*<sup>-/-</sup> dLN, LEC and BEC numbers were unchanged in FRC *Il17ra* (Supplementary Fig. 3f, g). Expression of *Fn1* and *Col1a1*, but not *Col3a1*, were also significantly decreased in FRC *Il17ra* mice compared to FRC<sup>ctrl</sup> (Supplementary Fig. 3h-j). Furthermore, numbers of FRC in LN of FRC *Il17ra* mice were significantly decreased on day 12 and 15 post-immunization (Fig. 3f,g). Thus we concluded that FRC-intrinsic IL-17 signaling is required for their successful proliferation during LN inflammation.

### FRC-intrinsic IL-17 signaling promotes antibody production

It might be expected that reduced numbers of FRCs would impact the adaptive immune system. However, numbers of CD4<sup>+</sup> T cells and B cells were not different between immunized FRC *Il17ra* and FRC<sup>ctrl</sup> mice (Fig. 4a, b). The disruption of FRC stromal architecture in immunized FRC *Il17ra* dLN did not disrupt B and T cell zones, and frequencies of naïve and effector T cell populations, as well as IL-17-producing T<sub>H</sub>17 cells, were unaffected (Fig. 4c, Supplementary Fig. 4a-c). Since already-differentiated T<sub>H</sub>17 cells produce IL-17 to then potentiate FRC proliferation, this is perhaps unsurprising in this acute model. However, there was a significant decrease in the frequency of germinal center B cells from immunized dLN when FRCs could not respond to IL-17 (Fig. 4d, Supplementary Fig. 4c), and a corresponding defect in induction of total immunoglobulin G (IgG) as well as MOG-specific IgG production (Fig. 4e, f). B cell activating factor (BAFF) is produced by FRCs to support B cell survival under homeostatic conditions<sup>10</sup>. IL-17 did not stimulate increased BAFF production in FRC *in vitro* (Fig. 4g). However, corresponding to reduced numbers of FRC, BAFF levels were significantly decreased in LN from immunized FRC *Il17ra* mice (Fig. 4h). Hence, lack of IL-17 signaling in FRC does not lead to global immune defects, but does cause impaired B cell responses, most likely through reduced availability of BAFF at a critical juncture for germinal center formation and maintenance.

### Colitis increases local IL-17-dependent FRC numbers

CFA is a potent long-acting adjuvant, and we wanted to test whether the IL-17-dependent increase in FRC numbers was more broadly applicable to inflamed LN. We therefore analyzed FRC in gut-draining mesenteric LN (MLN) during DSS colitis, a colon injury model in which IL-17 plays a protective role in restoring epithelial barrier integrity<sup>3, 4</sup>. As expected, *Il17ra*<sup>-/-</sup> mice developed more severe colitis, as determined by weight loss and colon length, while FRC<sup>IL17RA</sup> mice developed colitis of similar severity to controls since the gut epithelium response to IL-17 was intact (Fig. 5a, b, c, Supplementary Fig. 5a). Naïve mice with FRC-specific ablation of IL-17RA showed no difference in MLN FRC numbers compared to littermate controls, again confirming that IL-17 is not required for FRC development (Supplementary Fig. 5b). Numbers of FRC increased in the inflamed MLN of wild-type mice after administration of DSS compared to water controls (Fig. 5d). Strikingly, the colitis-driven MLN FRC population expansion was critically dependent on IL-17RA expression by FRC, rather than differing gut epithelial cell IL-17RA expression and disease severity in *Il17ra*<sup>-/-</sup> and FRC<sup>IL17RA</sup> mice (Fig. 5d). Therefore, these data support the

conclusion that FRC-intrinsic IL-17RA expression is required for FRC remodeling in the dLN during inflammation that elicits an IL-17 response, regardless of the type of peripheral tissue insult.

### IL-17 potentiates FRC proliferation and survival

To further understand how IL-17 promotes FRC activation, we performed transcriptomic analysis of dLN FRC isolated at day 12 post-immunization (Supplementary Fig. 6a). Known IL-17 targets were increased in wild-type compared to *Il17ra*<sup>-/-</sup> FRC (Fig. 6a), including genes encoding CXCL1, CXCL2, s100a8, s100a9, C/EBP $\beta$  and I $\kappa$ B $\zeta$ <sup>32</sup>. Fitting with decreased FRC numbers, gene set enrichment analysis (GSEA) showed significant dysregulation of the cell cycle pathway in *Il17ra*<sup>-/-</sup> FRC (Fig. 6b). There was a trend towards reduced expression of the cell cycle-associated protein ki67 in *Il17ra*<sup>-/-</sup> FRC in LN and a significant decrease in Ki67 in spleen (Fig. 6c and Supplementary Fig. 6b, c). Ki67 marks all cells that have initiated cell cycle. In fact, a number of the genes identified by GSEA to be increased in *Il17ra*<sup>-/-</sup> FRC are negative regulators of cell cycle, including *Trp53*, *Nek2*, *Tfdp1*, *Chek2* and *Rad17* (Fig. 6d). We therefore analyzed cell cycle stages and found that similar proportions of cells were in G2/M phase, but significantly fewer FRC *Il17ra* cells were in S phase compared to FRC<sup>ctrl</sup>, with an inverse trend towards increased G0/G1, which includes resting cells (Fig. 6e, Supplementary Fig. 6d). Fibroblasts have been shown to actively express genes that maintain cellular quiescence and suppress proliferation following *in vitro* triggers of quiescence such as growth factor withdrawal or cell-contact inhibition<sup>33</sup>. *Il17ra*<sup>-/-</sup> FRC had high expression of these fibroblast quiescence-associated genes when compared to wild-type FRC (Supplementary Fig. 6e), further supporting that cell cycle was stalled.

Cell cycle analysis also revealed increased apoptotic cells in IL-17RA-deficient FRC (Fig. 6e). There was no difference in total cell viability of digested wild-type and *Il17ra*<sup>-/-</sup> LN, in accord with similar total LN cell numbers (Supplementary Fig. 6f). However, GSEA pathway analysis supported significant upregulation of apoptotic pathways in IL-17RA-deficient FRC (Fig. 6f). Immunofluorescence staining confirmed significantly increased frequencies of cells that were positive for the apoptosis markers TUNEL and active caspase 3 in dLN of immunized *Il17ra*<sup>-/-</sup> mice compared to wild-type (Fig. 6g, h, Supplementary Fig. 6g, h). As further confirmation of the FRC-intrinsic role of IL-17 in maintaining FRC viability, there were significantly increased frequencies of apoptotic FRC in dLN from immunized FRC *Il17ra* compared to controls (Fig. 6i, Supplementary Fig. 6i). Taken together, these data indicate a critical role for IL-17 in promoting survival and continued proliferation of activated FRC.

### IL-17 drives metabolic reprogramming in proliferating FRC

Proliferation requires increased energy, and insufficient nutrient availability can be a cause of halted cell cycle and increased apoptosis in proliferating cells. Nutrient stress, including low glucose, leads to induction of autophagy through activation of AMPK<sup>34</sup>. *Il17ra*<sup>-/-</sup> FRC had increased expression of genes regulating autophagy (Fig. 7a), corresponding with increased activation of AMPK (Fig. 7b). GSK3 $\beta$  phosphorylation can also be an indicator of glucose uptake and glycolysis<sup>35</sup>, and IL-17 signaling has previously been associated with



regulation of GSK3 $\beta$  activity<sup>32</sup>. Indeed, *Il17ra*<sup>-/-</sup> FRC had decreased phosphorylation of GSK3 $\beta$  (Fig. 7c), further supporting a possible defect in energy metabolism in absence of IL-17 signaling. We therefore directly assessed the ability of FRC to take up glucose *in vivo* by injecting the fluorescent glucose analog 2-NBDG on day 12 post-immunization. FRC from immunized LN had significantly increased 2-NBDG uptake compared to naïve controls (Fig. 7d, e Supplementary Fig. 7a), while FRC from immunized *Il17ra*<sup>-/-</sup>, as well as FRC *Il17ra* LN and spleen, showed a striking defect in 2-NBDG uptake (Fig. 7d-g, Supplementary Fig. 7b). These data show that IL-17 signaling is required to increase the capacity for glucose uptake in proliferating FRC.

To determine the functional metabolic capacity of FRC activated in presence or absence of IL-17, we performed Seahorse extracellular flux analysis on pooled LN and spleen FRC from immunized wild-type and *Il17ra*<sup>-/-</sup> mice and compared to naïve wild-type controls. Corresponding to increased glucose uptake, aerobic glycolysis (as assessed by extracellular acidification rate (ECAR)), was increased following immunization in wild-type but not *Il17ra*<sup>-/-</sup> FRC (Fig. 7h). Similarly, wild-type FRC from immunized mice showed a strong increase in basal oxygen consumption rate (OCR), indicating enhanced oxidative phosphorylation (OXPHOS) (Fig. 7i), and correspondingly had a high spare respiratory capacity (SRC) compared to naïve FRC (Fig. 7i, j). In contrast, FRC from immunized *Il17ra*<sup>-/-</sup> LN had relatively lower basal OXPHOS rates with minimal SRC, more similar to naïve FRC (Fig. 7i, j). Gene expression data supported the IL-17RA-dependent increases in metabolic activity: compared to wild-type, FRC from *Il17ra*<sup>-/-</sup> immunized LN had low expression of the inflammation-induced glycolytic enzyme *Hk2*, and the rate limiting enzyme of mitochondrial fatty acid oxidation *Cpt1a*, along with several subunits of mitochondrial complex I NADH:ubiquinone oxidoreductase (NDUF) (Fig. 7k). However, mitochondrial mass per FRC was not dependent on IL-17RA (not shown). We further confirmed that *Cpt1a* protein expression was reduced when IL-17RA was specifically deleted in FRC (Fig. 7l and Supplementary Fig. 7c). These data thus demonstrate that IL-17 signaling is required for activated FRC to increase their glucose uptake, glycolysis and particularly mitochondrial bioenergetic activity, corresponding with the requirement for IL-17 signaling in promoting successful proliferation of FRC.

### IL-17 promotes metabolic changes through I $\kappa$ B $\zeta$

The data so far clearly implicate FRC-intrinsic IL-17 signaling in driving metabolic changes. However, FRC isolated from naïve LN and stimulated *in vitro* with IL-17 did not increase their glucose uptake, as assessed by 2-NBDG (Fig. 8a). In contrast, dLN FRC from mice immunized 6 days previously did increase 2-NBDG uptake in response to IL-17 stimulation (Fig. 8b). These data therefore suggest that IL-17 modulation of glucose absorption requires that cells have first received ‘priming’ signals in an inflamed LN.

We then tested the converse question: does prior IL-17 signaling *in vivo* alter the threshold for glucose uptake in response to distinct stimuli? Lipopolysaccharide (LPS), a prototypical TLR agonist known to drive glycolysis in myeloid cells, strongly increased glucose uptake in wild-type FRC from immunized LN, but not from naïve LN (Fig. 8c). Interestingly, FRC from immunized *Il17ra*<sup>-/-</sup> dLN did respond to LPS, but with significantly lower rates of

glucose uptake compared to wild-type FRC (Fig. 8c), supporting the idea that FRC receiving activating signals that render them responsive to further stimuli, but require IL-17 to reach full bioenergetic potential.

One intriguing link between the IL-17 and LPS signaling pathways is that they both induce I $\kappa$ B $\zeta$ , a co-activator of the NF- $\kappa$ B signal transduction pathway, to drive a subset of target inflammatory genes<sup>32,36</sup>. *Nfkbiz*, which encodes I $\kappa$ B $\zeta$ , was accordingly decreased in FRC from immunized *Il17ra*<sup>-/-</sup> mice compared to wild-type controls (Fig. 6a). IL-17 stimulation induced *Nfkbiz* expression in FRC from day 6 primed LN, as expected, and *Nfkbiz* expression was effectively depleted by siRNA (Fig. 8d). IL-17-induced expression of *Fnl* and *Colla1* were unaffected by *Nfkbiz* deletion, confirming that IL-17 signaling was intact and that I $\kappa$ B $\zeta$  does not regulate all IL-17 target genes (Fig. 8e, f). However, IL-17-stimulated glucose uptake was significantly decreased in *Nfkbiz*-deleted FRC (Fig. 8g). Furthermore, IL-17 induced *Cpt1a* expression in an *Nfkbiz*-dependent manner (Fig. 8h). Therefore we conclude that IL-17 directs metabolic shifts in activated FRC through induction of the transcriptional co-activator I $\kappa$ B $\zeta$ , leading to increased glucose uptake and expression of rate-limiting enzymes for mitochondrial oxidative phosphorylation.

## DISCUSSION

The most well-known function of IL-17 is to promote inflammation through induction of chemokines and cytokines that recruit and activate myeloid cells during inflammation<sup>32</sup>. However, IL-17 is implicated in diseases that include proliferation of non-immune cells as a pathological feature, and it has been reported that IL-17 signaling promotes proliferation of keratinocytes in models of psoriasis<sup>37</sup> and skin tumorigenesis<sup>38</sup>, and of oligodendrocyte precursors in a model of MS<sup>39</sup>. Our finding that IL-17 potentiates proliferation and survival of FRC through enhanced metabolic capacity now makes it very interesting to consider the potential contribution of IL-17-induced metabolic shifts in other cell targets in the context of pathologic tissue remodeling and fibrosis that accompany chronic inflammation. In addition, our data lead us to speculate that metabolic changes could underlie the synergistic activity of IL-17 with lymphotoxin in driving de novo FRC differentiation and proliferation for tertiary lymphoid follicle formation in autoimmunity<sup>6</sup>.

IL-17 is known to play a critical role in promoting B cell antibody responses. IL-17-deficient mice have defective IgA and IgG1 responses to oral immunization with cholera toxin<sup>40</sup>. Similarly, IL-17 is required for formation of GC and antibody class-switching in models of autoimmune disease<sup>41,42</sup>. The mechanisms by which IL-17 promotes B cell activation remain unclear. It has been proposed that T<sub>H</sub>17 cells promote intestinal IgA production through conversion to T follicular helper cells (T<sub>fh</sub>) that can then drive GC reactions<sup>43</sup>, however this does not explain the role of IL-17 itself. In immunized *Il17ra*<sup>-/-</sup> mice, T<sub>fh</sub> cells are present in normal numbers, but may not correctly localize to GC light zones<sup>44</sup>. Complete depletion of FRC in naïve CCL19<sup>cre</sup>DTX<sup>fl/fl</sup> mice results in reduced numbers of T and B cells, disorganized B cell follicles, and impaired adaptive immunity to influenza virus infection<sup>10</sup>. Although FRC numbers were reduced when they could not respond to IL-17, we did not find that *Il17ra* deficiency caused a clear defect in effector T cell responses in either EAE or DSS colitis. Similarly, total B cell and plasma cell frequencies were unchanged in



EAE, suggesting that impaired antibody response in *Il17ra*<sup>-/-</sup> mice is not a simple outcome of reduced FRC numbers leading to reduced T and B cell survival. The connection between IL-17 signaling in FRC and antibody response is particularly interesting in context of autoimmune diseases, where both autoantibody and T<sub>H</sub>17 responses are commonly present.

Unlike lymphotoxin, IL-17 does not appear to be required for development of the FRC network. Instead, the role of IL-17 in promoting metabolic fitness was restricted to inflammation-induced FRC proliferation. The corresponding finding that FRC from naïve mice were unresponsive to IL-17-stimulated glucose uptake leads us to speculate that IL-17 acts as ‘signal 2’ in FRC activation, while prior signals such as clec2, mechanical stretch or lymphotoxin provide ‘signal 1’ to drive proliferation. Given the roles of FRC in SLO homeostasis, it seems likely that this provides an extra layer of regulation to avoid tolerance breakdown due to inappropriate activation of FRC. It is thus interesting to speculate that IL-17-stimulated FRC are more prone to inappropriate or exaggerated responses to activating stimuli due to their heightened metabolic status, providing a clue to the involvement of IL-17 in loss of tolerance and in relapses that characterize autoimmune inflammation.

IL-17 is itself a relatively weak activator of NF- $\kappa$ B signaling<sup>45</sup>, but strongly synergizes with other NF- $\kappa$ B-activating cytokines, including TNF and lymphotoxin<sup>32</sup>. IL-17 signaling will inevitably synergize with additional cytokines present in the inflamed local milieu, making the profound impact of IL-17 deficiency even more remarkable under T<sub>H</sub>17-activating conditions. The observation that IL-17 signaling lowered the threshold of activated FRC to stimulation from LPS suggested that the heightened metabolic function of IL-17-stimulated stromal cells is an additional *modus operandi* for the synergistic activities of IL-17 with a surprising range of cytokines and TLR stimuli.

IL-17 signaling not only directly modulates gene expression through NF- $\kappa$ B activation, it also strongly alters signaling transduction networks through induction of transcriptional regulators<sup>32</sup>. I $\kappa$ B $\zeta$  is an inducible transcriptional coactivator with NF- $\kappa$ B in driving inflammatory cytokine expression, in response to stimulation of either the IL-17-Act1<sup>45</sup> or TLR/IL-1-Myd88 pathways<sup>36</sup>. I $\kappa$ B $\zeta$  expression is negatively regulated by Regnase1<sup>29</sup>, corresponding to increased FRC numbers in mice with reduced Regnase1 activity. Although I $\kappa$ B $\zeta$  has not previously been linked to metabolism, it has been shown to promote survival of epithelial cells<sup>46</sup>, and B cell lymphoma cells<sup>47</sup>, the latter through co-activation of NF- $\kappa$ B. Indeed, NF- $\kappa$ B activity links metabolism to cell survival in cancer cells by increasing mitochondrial respiration<sup>48, 49</sup> and glucose uptake<sup>50</sup>. It will be interesting in future to further investigate molecular mechanisms by which I $\kappa$ B $\zeta$  regulates metabolism, and the associated influence on inflammation. Since I $\kappa$ B $\zeta$  did not regulate ECM production, this also suggests that divergent IL-17 signaling pathways could be targeted in disease states to separate tissue remodeling and fibrosis effects from cell metabolism and proliferation.

In conclusion, we show that during T<sub>H</sub>17 cell differentiation in draining LN, IL-17 signals to FRC had a profound impact on LN stromal organization by promoting FRC activation through a phenotypic switch from quiescence to a highly metabolically active phenotype. Most strikingly, IL-17 deficiency resulted in stalled proliferation and increased apoptosis of

FRC, accompanied by signs of severe metabolic stress. Hence these data reveal the intimate connections between differentiation of a pro-inflammatory effector T<sub>H</sub>17 response and alterations in the FRC network that support the inflamed hypercellular LN environment, with outcomes on B cell adaptive responses. These findings provide new insight into mechanisms by which T<sub>H</sub>17 cells can mediate inflammation and tissue remodeling in lymphoid organs, and support further investigation of this role for IL-17 in peripheral tissue targets of T<sub>H</sub>17-dependent inflammation.

## METHODS

### Mice

The following mice were used: C57BL/6, *Il17a*<sup>-/-</sup>, OT-II, *Il17ra*<sup>fl/fl</sup> <sup>51</sup> mice (Jackson Laboratory), *Act1*<sup>-/-</sup> (*Traf3ip2*<sup>-/-</sup>) mice<sup>52</sup>, CCL19Cre mice (EMMA repository, Infrafrontier), *Il23r*<sup>-/-</sup> mice<sup>53</sup>, *Il17ra*<sup>-/-</sup> (Amgen, Inc), Regnase1<sup>+/-</sup> (*Zc3h12a*<sup>+/-</sup>) mice<sup>54</sup>. All experiments included age- and sex-matched controls. Mice were housed under SPF conditions in an AAALAC-approved facility. Protocols were approved by the University of Pittsburgh IACUC and adhered to guidelines in the Guide for the Care and Use of Laboratory Animals of the NIH.

### Experimental Autoimmune Encephalomyelitis

Mice were immunized subcutaneously in 2 sites on the back with 100 µg myelin oligodendrocyte glycoprotein (MOG) peptide (35–55) (Biosynthesis) emulsified with Complete Freund's Adjuvant (CFA) with *M. tuberculosis* strain H37Ra (DIFCO Laboratories). Mice also received 100 ng pertussis toxin (List Biological Laboratories) i.p. on day 0 and day 2. Mice were assessed daily and scored as follows: 1, flaccid tail; 2, impaired righting reflex and hindlimb weakness; 3, partial hindlimb paralysis; 4, complete hindlimb paralysis; 5, hindlimb paralysis with partial forelimb paralysis; 6, moribund. For IL-17 neutralization studies, mice were treated i.p. with 100 µg of anti-IL-17A (clone 17F3, BioXCell) or mouse IgG1 isotype control antibody (clone MOPC-21, BioXCell) every 3 days starting at day of EAE immunization till day 12 of immunization.

### OT-II transfer

Wild-type or *Il23r*<sup>-/-</sup> recipient mice received  $1 \times 10^5$  *Il23r*<sup>-/-</sup> or *Il23r*<sup>+/+</sup> OT-II CD4<sup>+</sup> T cells i.p. 1 day before being immunized subcutaneously in the flank with 100 µg OVA (323–339) in CFA.

### DSS colitis

Mice received 2.5% DSS (36,000–50,000 M.W.; MP Biomedicals) in their drinking water for 7 days, followed by 3 days of distilled water without DSS. Control animals received distilled water for the entire period. Mice were monitored daily for body weight and sacrificed on day 10 for MLN isolation.

## qPCR

RNA isolated with RNeasy Mini Kits (QIAGEN), cDNA generated with Superscript III First Strand kits (Invitrogen), followed by real-time RT-PCR (qPCR) using SYBR Green Master mix with ROX (Invitrogen) and RT<sup>2</sup> qPCR Primers (QIAGEN) on a 7300 Real Time instrument (Applied Biosystems). Gene expression normalized to GAPDH.

## FRC preparation for flow cytometry

LNs, and spleens where indicated, were incubated in digestion medium (RPMI, 0.1 mg/ml DNase I (Invitrogen), 0.1–0.2 mg/ml liberase (Roche) and 0.8 mg/ml dispase (Roche)<sup>19</sup>. Collected single-cell suspensions were filtered. Spleen samples underwent red blood cell lysis. For flow cytometry, cells were stained with GhostDye510 viability dye (Tonbo Biosciences) in PBS, followed by labeling with CD45 (30-F11, Invitrogen), CD45.2 (104, BD Biosciences), PDPN (8.1.1, Biolegend), CD31 (MEC 13.3, BD Biosciences) and Ki67 (SolA15, eBioscience), Madcam-1 (MECA-89, BD), CD21/CD35 (Clone: 7G6, BD), Cpt1a (8F6AE9, Abcam), CD4 (GK1.5, Invitrogen), B220 (RA3–6B2, BD), IL-17RA (PAJ-17R, Invitrogen) and CountBright™ Absolute Counting Beads (Molecular Probes). For detection of apoptosis, FRC were stained with FITC Active Caspase-3 Apoptosis Kit (BD Biosciences), as per manufacturer's protocol. For *in vivo* cell cycle analysis, mice were injected i.p. with 1 mg of bromodeoxyuridine (BrdU flow kit; BD Biosciences) 24 h before sacrifice. Data acquired with a FACS Fortessa (BD Biosciences), analyzed using FlowJo (Tree Star).

## Histology and Immunocytochemistry

Sections from frozen LNs were fixed in 4% paraformaldehyde, stained with Masson Trichrome (Sigma) to detect collagen deposition according to manufacturer's instructions; Primary antibodies used for immunofluorescence staining: ERTR7 (Santacruz; sc73355), Fibronectin (Thermoscientific; FBN11), CD4 (BioLegend; GK1.5), B220 (BioLegend; RA3–6B2) and cleaved caspase-3 (Cell Signaling; D175), TUNEL staining performed using apoptosis detection kit (Millipore). Images acquired with EVOS FL Auto microscope (Life Technologies). TUNEL<sup>+</sup> cells enumerated in 6–10 randomly selected high-powered fields (400X) per slide.

## RNA sequencing and GSEA

Live CD45<sup>-</sup>CD31<sup>-</sup>PDPN<sup>+</sup> FRC from wild-type and *Il17ra*<sup>-/-</sup> mice (4/group, day 12 post-immunization) were sorted on a FACS Aria directly into SmartSeq low-input RNA kit lysis buffer. DNA libraries were prepared (Nextera XT kit) and RNA-Sequencing was performed on Illumina NextSeq500 by Health Sciences Sequencing Core at University of Pittsburgh. Raw sequence reads were cleaned for adapter sequences using Trimmomatic with default parameters<sup>55</sup>. Trimmed reads were mapped onto mouse genome build mm9 using TopHat2.1.1 and gene expression values (FPKM; fragments per kilobase exon per million mapped reads) calculated using Cufflinks2.2.1<sup>56</sup>. Unbiased hierarchical clustering of differentially expressed genes with  $P < 0.05$  calculated using Partek software. Relative expression shown in heatmaps was calculated as fpkm for each sample divided by mean expression of that gene in all samples. Gene set enrichment analysis (GSEA) from the Broad

Institute (<http://www.broad.mit.edu/gsea>) was used to calculate enrichment of genes in each set. Cell cycle and apoptosis pathway gene lists were assembled using Qiagen's SABiosciences pathway PCR arrays.

### Antibody ELISA

Total IgG concentrations in serum detected by mouse IgG ELISA kit (Invitrogen). For detection of MOG-specific antibody in serum, 96-well-plates were coated overnight with recombinant MOG protein (AnaSpec) (10 µg/ml), blocked for 2 h, then incubated with sera (serial dilutions starting from 1:100) for 3 h. After washing, antibody bound to rMOG were detected by HRP-labeled anti-IgG antibody, and developed using mouse IgG ELISA kit (Invitrogen), O.D. values of 1:333 dilution were normalized relative to standard curve for anti-IgG for each experiment, since standards for anti-MOG IgG are not commercially available.

### FRC isolation

LNs and spleens digested as described above. Resulting cell suspension was incubated with anti-CD31-APC (MEC13.3; BioLegend) and anti-CD45-APC (30-F11; BioLegend), followed by anti-APC selection cocktail and magnetic particles (EasySep; StemCell Technologies). After negative selection (MACS column, Miltenyi Biotech), the flow-through containing FRC was further incubated with anti-PDPN-PE (8.1.1; BioLegend) and anti-PE selection cocktail and magnetic particles (EasySep; StemCell Technologies) followed by positive selection. This typically resulted in 80–95% CD45<sup>+</sup>PDPN<sup>+</sup>CD31<sup>-</sup> FRCs.

### Immunoblotting

CD45<sup>+</sup>CD31<sup>-</sup> cells isolated from LNs as described above were immediately lysed on ice in lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 2 mM NaF and 0.01% NP40) containing 1 mM sodium orthovanadate (phosphatase inhibitor), 50 mM PMSF, and protease inhibitor cocktail (Calbiochem). Samples were boiled in 4× sample buffer (Bio-Rad) and immunoblotted using anti-Phospho-AMPKα and anti-AMPKα (Cell Signaling Technology).

### Seahorse metabolic assay

FRC were plated on Cell-Tak coated Seahorse culture plates (50,000 cells/well) in DMEM with 25 mM glucose, 1% BSA, 1 mM pyruvate, 2 mM glutamine, and analyzed using a Seahorse XFe96 (Agilent). EACR (Basal extracellular acidification) and OCR (oxygen consumption rates) for 160 min, as cells were stimulated with oligomycin (2 mM), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP); 0.5 mM, 2-deoxyglucose (100 mM) and rotenone/antimycin A (100 mM) to obtain maximal and control OCR values. SPR (Spare respiratory capacity) measured as the difference between basal and maximal OCR values before and after addition of FCCP.

### siRNA transfection

Isolated FRC were rested overnight then transfected with 50nM ON-TARGETplus SMARTpool siRNAs targeting *Nfkbiz* or scrambled control (Dharmacon) in DharmaFECT

Reagent 1 (Dharmacon) for 24 h before stimulation with 200ng/ml IL-17 (Peprotech) for 12hr.

### Glucose uptake

*In vivo*, 500 nM of 2-NBDG (2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose) (Cayman Chemicals) was injected via tail vein 30 min prior to sacrifice. *In vitro*, 2-NBDG was added for final 30 min. of culture. Uptake of 2-NBDG (a fluorescent glucose analog) was then assessed by flow cytometry. Glucose uptake following LPS stimulation *ex vivo* measured by Glucose Uptake-Glo™ Assay kit (Promega) according to the manufacturer's instructions.

### Statistics

Experimental results were analyzed for significance using ONE-WAY ANOVA (for multiple groups) or Student's *t*-test, except EAE clinical data analyzed by Mann-Whitney test on each day of scoring. Statistical analyses were performed using GraphPad Prism. *P* values are shown as \*, *P* < 0.05, \*\*, *P* < 0.01, and \*\*\*, *P* < 0.001, where statistical significance was found, and all data are represented as mean ± standard deviation.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### ACKNOWLEDGEMENTS

Funding for this study provided by NIH AI110822, AI128991 (M.J.M.); NIH T32-AI089443 (I.R.), NIH DK104680 (P.S.B.), NIH DE022550, DE023815 and AI107825 (S.L.G.), R.K. Mellon Institute for Pediatric Research (T.W.H.), AACR SU2C-AACR-IRG-04-16 and NIH DP2AI136598 (G.M.D.). This research was supported in part by the University of Pittsburgh Center for Research Computing through the resources provided. We thank V. Kuchroo (Harvard University) for *Il23r*<sup>-/-</sup> mice, P. Kolattukudy (University of Central Florida) for *zc3h12a*<sup>+/-</sup> (Regnase1)<sup>+/-</sup> mice, J. Kolls (Tulane University) for *Il17ra*<sup>fl/fl</sup> mice (now available at JAX labs), and Louise D'Cruz for critical reading of the manuscript.

### REFERENCES

1. Patel DD & Kuchroo VK Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions. *Immunity* 43, 1040–1051 (2015). [PubMed: 26682981]
2. Gaffen SL, Jain R, Garg AV & Cua DJ The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. *Nat Rev Immunol* 14, 585–600 (2014). [PubMed: 25145755]
3. Lee JS et al. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. *Immunity* 43, 727–738 (2015). [PubMed: 26431948]
4. Maxwell JR et al. Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. *Immunity* 43, 739–750 (2015). [PubMed: 26431947]
5. Grogan JL & Ouyang W A role for Th17 cells in the regulation of tertiary lymphoid follicles. *Eur J Immunol* 42, 2255–2262 (2012). [PubMed: 22949324]
6. Pikor NB et al. Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation. *Immunity* 43, 1160–1173 (2015). [PubMed: 26682987]
7. Brown FD & Turley SJ Fibroblastic reticular cells: organization and regulation of the T lymphocyte life cycle. *J Immunol* 194, 1389–1394 (2015). [PubMed: 25663676]
8. Rodda LB et al. Single-Cell RNA Sequencing of Lymph Node Stromal Cells Reveals Niche-Associated Heterogeneity. *Immunity* 48, 1014–1028 e1016 (2018). [PubMed: 29752062]

9. Huang HY et al. Identification of a new subset of lymph node stromal cells involved in regulating plasma cell homeostasis. *Proc Natl Acad Sci U S A* 115, E6826–E6835 (2018). [PubMed: 29967180]
10. Cremasco V et al. B cell homeostasis and follicle confines are governed by fibroblastic reticular cells. *Nat Immunol* 15, 973–981 (2014). [PubMed: 25151489]
11. Chai Q et al. Maturation of lymph node fibroblastic reticular cells from myofibroblastic precursors is critical for antiviral immunity. *Immunity* 38, 1013–1024 (2013). [PubMed: 23623380]
12. Zeng M et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. *J Clin Invest* 121, 998–1008 (2011). [PubMed: 21393864]
13. Estes JD et al. Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy. *J Infect Dis* 211, 744–754 (2015). [PubMed: 25246534]
14. Kityo C et al. Lymphoid tissue fibrosis is associated with impaired vaccine responses. *J Clin Invest* (2018).
15. Khan O et al. Regulation of T cell priming by lymphoid stroma. *PLoS One* 6, e26138 (2011). [PubMed: 22110583]
16. Lukacs-Kornek V et al. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. *Nat Immunol* 12, 1096–1104 (2011). [PubMed: 21926986]
17. Siegert S et al. Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by producing nitric oxide. *PLoS One* 6, e27618 (2011). [PubMed: 22110693]
18. Gil-Cruz C et al. Fibroblastic reticular cells regulate intestinal inflammation via IL-15-mediated control of group 1 ILCs. *Nat Immunol* 17, 1388–1396 (2016). [PubMed: 27798617]
19. Fletcher AL et al. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. *J Exp Med* 207, 689–697 (2010). [PubMed: 20308362]
20. Dubrot J et al. Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4(+) T cell tolerance. *J Exp Med* 211, 1153–1166 (2014). [PubMed: 24842370]
21. Cyster JG Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. *Annu Rev Immunol* 23, 127–159 (2005). [PubMed: 15771568]
22. Astarita JL et al. The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. *Nat Immunol* 16, 75–84 (2015). [PubMed: 25347465]
23. Chyou S et al. Coordinated regulation of lymph node vascular-stromal growth first by CD11c+ cells and then by T and B cells. *J Immunol* 187, 5558–5567 (2011). [PubMed: 22031764]
24. Yang CY et al. Trapping of naive lymphocytes triggers rapid growth and remodeling of the fibroblast network in reactive murine lymph nodes. *Proc Natl Acad Sci U S A* 111, E109–118 (2014). [PubMed: 24367096]
25. Katakai T, Hara T, Sugai M, Gonda H & Shimizu A Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. *J Exp Med* 200, 783–795 (2004). [PubMed: 15381731]
26. Teesalu T, Hinkkanen AE & Vaheri A Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. *Am J Pathol* 159, 2227–2237 (2001). [PubMed: 11733372]
27. Han MH et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. *Nature* 451, 1076–1081 (2008). [PubMed: 18278032]
28. McGeachy MJ et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. *Nat Immunol* 10, 314–324 (2009). [PubMed: 19182808]
29. Garg AV et al. MCP1 Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and Inflammation. *Immunity* 43, 475–487 (2015). [PubMed: 26320658]
30. Khader SA, Gaffen SL & Kolls JK Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. *Mucosal Immunol* 2, 403–411 (2009). [PubMed: 19587639]




31. Chung J et al. Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. *J Clin Invest* 127, 1574–1588 (2017). [PubMed: 28319044]
32. Amatya N, Garg AV & Gaffen SL IL-17 Signaling: The Yin and the Yang. *Trends Immunol* 38, 310–322 (2017). [PubMed: 28254169]
33. Collier HA, Sang L & Roberts JM A new description of cellular quiescence. *PLoS Biol* 4, e83 (2006). [PubMed: 16509772]
34. Okoshi R et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. *J Biol Chem* 283, 3979–3987 (2008). [PubMed: 18056705]
35. Loberg RD, Vesely E & Brosius FC 3rd. Enhanced glycogen synthase kinase-3beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. *J Biol Chem* 277, 41667–41673 (2002). [PubMed: 12200436]
36. Yamamoto M et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. *Nature* 430, 218–222 (2004). [PubMed: 15241416]
37. Ha HL et al. IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. *Proc Natl Acad Sci U S A* 111, E3422–3431 (2014). [PubMed: 25092341]
38. Wu L et al. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. *J Exp Med* 212, 1571–1587 (2015). [PubMed: 26347473]
39. Wang C et al. IL-17 induced NOTCH1 activation in oligodendrocyte progenitor cells enhances proliferation and inflammatory gene expression. *Nat Commun* 8, 15508 (2017). [PubMed: 28561022]
40. Datta SK et al. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. *Proc Natl Acad Sci U S A* 107, 10638–10643 (2010). [PubMed: 20479237]
41. Hsu HC et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. *Nat Immunol* 9, 166–175 (2008). [PubMed: 18157131]
42. Mitsdoerffer M et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. *Proc Natl Acad Sci U S A* 107, 14292–14297 (2010). [PubMed: 20660725]
43. Hirota K et al. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. *Nat Immunol* 14, 372–379 (2013). [PubMed: 23475182]
44. Ding Y et al. IL-17RA is essential for optimal localization of follicular Th cells in the germinal center light zone to promote autoantibody-producing B cells. *J Immunol* 191, 1614–1624 (2013). [PubMed: 23858031]
45. Sonder SU et al. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. *J Biol Chem* 286, 12881–12890 (2011). [PubMed: 21335551]
46. Okuma A et al. Enhanced apoptosis by disruption of the STAT3-IkappaB-zeta signaling pathway in epithelial cells induces Sjogren’s syndrome-like autoimmune disease. *Immunity* 38, 450–460 (2013). [PubMed: 23453632]
47. Nogai H et al. IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL. *Blood* 122, 2242–2250 (2013). [PubMed: 23869088]
48. Mauro C et al. NF-kappaB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. *Nat Cell Biol* 13, 1272–1279 (2011). [PubMed: 21968997]
49. Johnson RF, Witzel II & Perkins ND p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-kappaB. *Cancer Res* 71, 5588–5597 (2011). [PubMed: 21742773]
50. Sommermann TG, O’Neill K, Plas DR & Cahir-McFarland E IKKbeta and NF-kappaB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. *Cancer Res* 71, 7291–7300 (2011). [PubMed: 21987722]

## Methods references:

51. Kumar P et al. Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota and Autoimmune Inflammation. *Immunity* 44, 659–671 (2016). [PubMed: 26982366]


52. Claudio E et al. The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. *J Immunol* 182, 1617–1630 (2009). [PubMed: 19155511]
53. Awasthi A et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. *J Immunol* 182, 5904–5908 (2009). [PubMed: 19414740]
54. Jin Z, Liang J, Wang J & Kolattukudy PE MCP-induced protein 1 mediates the minocycline-induced neuroprotection against cerebral ischemia/reperfusion injury in vitro and in vivo. *J Neuroinflammation* 12, 39 (2015). [PubMed: 25888869]
55. Bolger AM, Lohse M & Usadel B Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30, 2114–2120 (2014). [PubMed: 24695404]
56. Trapnell C et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 7, 562–578 (2012). [PubMed: 22383036]



**Figure 1: IL-23R-IL-17 axis drives increased fibronectin in dLN following immunization for EAE**


**A:** *Fn1* gene expression (relative values normalized to *Gapdh*) in inguinal LN from naïve wild-type mice and from wild-type and *Il23r<sup>-/-</sup>* mice analyzed on day 15 post-immunization with MOG(35–55) in CFA. **B,C:** Wild-type or *Il23r<sup>-/-</sup>* OT-II T cells were transferred to wild-type or *Il23r<sup>-/-</sup>* hosts, as indicated, and mice were immunized with OVA (323–339) in CFA the following day. *Il17a* (**B**) and *Fn1* (**C**) gene expression were analyzed on day 15 in inguinal LN. **D-L:** Indicated mice were immunized with MOG(35–55) in CFA, and dLN

analyzed on day 15 post-immunization with LN from naïve mice as controls; **D-F**: *Fn1* gene expression relative to *Gapdh*; Data in (A-F) are representative of two independent experiments. Data show mean  $\pm$  S.D; each symbol represents an individual mouse **G**: Immunofluorescence staining of fibronectin; **H**: *Col1a1* gene expression; Data representative of two independent experiments. Data show mean  $\pm$  S.D; each symbol represents an individual mouse **I**: Collagen stained by Masson's Trichrome (blue) with hematoxylin (pink); **J-L**: Gross appearance (**J**), weights (**K**) and total cell counts (**L**). Data in (K-L) show mean  $\pm$  S.D. pooled from 2–3 experiments, each symbol represents an individual mouse, except G, I, J are representative images from n=4 mice/group. G and I were repeated twice with similar results. P values calculated by one-way ANOVA except F,K and L by Student's t-test, \* P<0.05, \*\* P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.



### Figure 2: FRC population expansion during T<sub>H</sub>17 response requires IL-17 signaling


Wild-type or indicated knockout mice were immunized for EAE and dLN analyzed on day 15, compared to naïve wild-type LN by flow cytometry. **A-D:** Numbers of CD45<sup>+</sup>PDPN<sup>+</sup>CD31<sup>-</sup> FRC cells in dLN (A,C,D) and spleen (B) from indicated mice. **E:** Numbers of CD45<sup>+</sup>PDPN<sup>+</sup>CD31<sup>+</sup> lymphatic endothelial cells; **F:** numbers of CD45<sup>+</sup>PDPN<sup>-</sup>CD31<sup>+</sup> blood endothelial cells; **G:** numbers of PDPN<sup>+</sup>CD21<sup>+</sup>CD35<sup>+</sup> follicular dendritic cells (FDC). **H:** numbers of PDPN<sup>+</sup>MadCAM1<sup>+</sup> marginal zone reticular cells (MRC); Data in (A-H) show mean  $\pm$  S.D. pooled from 2–3 experiments, each symbol represents an individual mouse. P values calculated by one-way ANOVA except C,D,G and H by Student's t-test, \* P<0.05, \*\* P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.



**Figure 3: FRC-specific ablation of IL-17RA results in defective expansion**


**A,B:** Gene expression of lymphotoxin  $\alpha$  (*Lta*) (**A**) and lymphotoxin  $\beta$  (*Ltb*) (**B**) in naïve, wild-type EAE and 17RA<sup>-/-</sup>EAE inguinal LN on day 15 post-immunization. Data in (A-B) are representative of two independent experiments. Data show mean  $\pm$  S.D; each symbol represents an individual mouse **C:** Numbers of FRC cells in dLN from wild-type mice immunized for EAE with administration of 100ug anti-IL-17 or isotype control, analyzed by flow cytometry on day 15. **D:** Frequencies of neutrophils in indicated naïve and day 15 EAE LN. **E-G:** CCL19Cre x IL17RA<sup>fl/fl</sup> (FRC *Il17ra*) mice and CCL19Cre x IL17RA<sup>fl/+</sup> littermate controls (FRC<sup>Ctrl</sup>) were immunized for EAE and dLN analyzed on day 15 (except F is day 12) by flow cytometry for neutrophils (E) and numbers of FRC (F,G). Data in (C-G) are pooled from 2–3 experiments, represented as mean  $\pm$  S.D. and each symbol represents an individual mouse. P values calculated by one-way ANOVA except C,E,F and G by Student's t-test, \* P<0.05, \*\* P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.





**Figure 4: IL-17 signaling in FRC is required to support germinal centers and antibody production.**

FRC<sup>ctrl</sup> and FRC *Il17ra* mice were immunized with MOG(35–55) in CFA, and frequencies and phenotype of adaptive response was analyzed on days 12–14; **A**: Frequency of CD4<sup>+</sup> T cells out of total live cells, **B**: Frequency of B220<sup>+</sup> B cells out of live cells; **C**: Frequency of IL-17<sup>+</sup> cells out of live CD4<sup>+</sup> T cells following stimulation with PMA/ionomycin; **D**: Frequency of germinal center B cells analyzed as GL-7<sup>+</sup>CD95<sup>+</sup> cells out of live B220<sup>+</sup> cells; **E**: Concentration of total IgG in serum, **F**: Concentration of MOG-specific IgG in serum, Data in (A–F) are pooled from 2–3 experiments, represented as mean  $\pm$  S.D. and each symbol represents an individual mouse. **G**: GP38<sup>+</sup> FRC were isolated from day 6 immunized wild-type LN and spleen, and stimulated with IL-17 for 12 hours, then gene expression of *Tnfsf13b* encoding BAFF was analyzed by qPCR and normalized to GAPDH; **H**: Gene expression of *Tnfsf13b* analyzed by qPCR in dLN on day 14 post-immunization. Data in (G–H) are representative of two independent experiments. Data show mean  $\pm$  S.D.; each symbol represents an individual mouse. P values calculated by one-way ANOVA except A–D and G by Student's t-test, \* P<0.05, \*\* P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.



**Figure 5: Acute colon inflammation drives IL-17-dependent increase of FRC in mesenteric LN.** FRC<sup>ctrl</sup>, FRC<sup>117ra</sup> and 117ra<sup>-/-</sup> mice received 2.5% DSS in drinking water for 7 days followed by 3 days of water, naïve control received normal drinking water. **A:** Body weights shown as % of starting weight; **B:** representative H&E images of day 10 colon in indicated naïve and DSS mice; **C:** Colon length on day 10; **D:** Numbers of FRC in mesenteric LN (MLN) analyzed on day 10 by flow cytometry gating on live CD45<sup>-</sup>CD31<sup>-</sup>PDPN<sup>+</sup> cells. Data in A is pooled from two independent experiments and shown as mean  $\pm$  S.D. (Naïve=7, FRC<sup>ctrl</sup>=6, FRC<sup>117ra</sup>=7 and 117ra<sup>-/-</sup>= 6 mice), Data in B is representative


images from n=4 mice/group repeated twice with similar results, and data in (C-D) are pooled from 2 experiments, represented as mean  $\pm$  S.D. and each symbol represents an individual mouse. P values calculated by one-way ANOVA, \* P<0.05, \*\* P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.

Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript



**Figure 6: IL-17 promotes proliferation and cell survival of inflamed LN FRC**

**A:** Wild-type and IL-17RA<sup>-/-</sup> FRC (live CD45<sup>+</sup>CD31<sup>+</sup>PDPN<sup>+</sup> cells) were sorted from dLN (N=2, each sample was pooled from 4 mice) on day 12 post-immunization for RNA-sequencing, heat map shows relative expression of IL-17-responsive genes in wild-type FRCs compared to IL-17RA<sup>-/-</sup> FRCs, \* indicates genes with p<0.05 in global differential gene expression analysis (Partek). **B:** Gene set enrichment analysis (GSEA) of cell cycle pathway; **C:** Frequency of Ki67<sup>+</sup> cells out of CD45<sup>+</sup>CD31<sup>+</sup>PDPN<sup>+</sup> FRCs determined by flow cytometry in indicated groups in inguinal LN, day 12 post-immunization. Data pooled

from 2 experiments, represented as mean  $\pm$  S.D. and each symbol represents an individual mouse. **D**: Heat map of GSEA-identified cell cycle pathway genes, \* indicates genes with  $p < 0.05$  in global differential gene expression analysis (Partek).; **E**: FRC<sup>ctrl</sup> and FRC *Il17ra* mice were immunized for EAE, and BrdU pulse administered 24hr before harvest, cell cycle status of live CD45<sup>-</sup>PDPN<sup>+</sup>CD31<sup>-</sup> splenic FRC analyzed by BrdU and 7-AAD staining on day 12 post-immunization; Data pooled from 2 experiments, represented as mean  $\pm$  S.D. and each symbol represents an individual mouse **F**: Gene set enrichment analysis of apoptosis pathway; **G**: ERTR7 and TUNEL immunofluorescence analysis in dLN on day 15 post-immunization; Data are representative images from n=4 mice/group repeated twice with similar results, **H**: Quantification of TUNEL<sup>+</sup> cells in ERTR7<sup>+</sup> zones from indicated LN, each symbol represents counts from a separate field of view, data pooled from two separate experiments; **I**: Frequency of FRC staining positive for active caspase 3 in dLN of FRC<sup>ctrl</sup> and FRC *Il17ra* mice on day 15 post-immunization analyzed by flow cytometry. Data pooled from 2 experiments, represented as mean  $\pm$  S.D. and each symbol represents an individual mouse. P values calculated by one-way ANOVA except I by Student's t-test, \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .




**Figure 7: FRC undergo an IL-17-dependent metabolic shift during inflammation.**

**A:** Relative expression of markers of autophagy (from RNA-Seq analysis described in Fig 6), \* indicates genes with  $p < 0.05$  in global differential gene expression analysis (Partek); **B:** FRC from wild-type and *Il17ra*<sup>-/-</sup> EAE inguinal LN on day 12 post-immunization, immunoblotted for Phosphorylated AMPK $\alpha$  and total AMPK $\alpha$ . Data are representative of two independent experiments; **C:** pGSK3 $\beta$  analyzed by flow cytometry in FRC isolated from naïve, wild-type EAE and *Il17ra*<sup>-/-</sup> EAE dLN on day 12 post-immunization. Data are representative of two independent experiments with  $n = 3-4$  mice/group; **D,E:** Frequencies of



2-NBDG<sup>+</sup> FRC (**D**) and geometric mean fluorescence intensity (GMFI) of 2-NBDG in total FRC (**E**) in dLN from indicated mice injected with 2-NBDG 30 minutes prior to sacrifice and analyzed on day 12 post-immunization, gating on live CD45<sup>-</sup>CD31<sup>-</sup>PDPN<sup>+</sup> cells. Each symbol represents inguinal LN from separate mice. **F,G**: Frequencies of 2-NBDG<sup>+</sup> FRC (**F**) and GMFI of 2-NBDG in total FRC (**G**) in dLN from FRC<sup>ctrl</sup> and FRC *Il17ra* treated as in D. Data in (D-G) are pooled from 2 experiments, represented as mean +/- S.D. and each symbol represents an individual mouse. **H-I**: FRCs isolated as CD45<sup>-</sup>CD31<sup>-</sup>PDPN<sup>+</sup> cells from naïve, wild-type EAE and *Il17ra*<sup>-/-</sup> EAE dLN and spleen on day 12 post-immunization were subjected to Seahorse metabolic analysis; **H**: Extracellular acidification rate (ECAR); **I**: Oxygen consumption rate (OCR) trace; **J**: spare respiratory capacity (SRC) calculated as the difference between initial OCR values and maximal OCR values achieved after FCCP uncoupling from FRC analyzed by Seahorse as in F. H-J show mean +/- S.D. of pooled data from 3 experiments, each performed with pooled FRC from 2–3 mice/group and 2–5 technical replicates; **K**: heatmap of relative expression of metabolic genes on day 12 post-immunization (p<0.05), RNA-Seq as described in Figure 6. **L**: Cpt1a expression in day 12 FRC analyze by flow cytometry of dLN from FRC<sup>ctrl</sup> and FRC *Il17ra* mice on day 12 of EAE. Data pooled from 2 experiments, represented as mean +/- S.D. and each symbol represents an individual mouse. P values calculated by one-way ANOVA except F, G and L by Student's t-test, \* P<0.05, \*\* P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.



**Figure 8: IL-17 promotes glucose uptake through  $I\kappa B\zeta$  expression**

FRCs were isolated from wild-type dLN and spleen on day 6 post-immunization for EAE or naïve as indicated in A-C. **A,B:** FRC were stimulated in vitro with IL-17 followed by incubation with 2-NBDG to assess glucose uptake, **A** shows representative FACS plots, **B** shows GMFI of pooled data. Data in (A-B) are representative of two independent experiments, show mean  $\pm$  S.D with  $n=3$  mice/group and were repeated thrice with similar results; **C:** FRCs from naïve, wild-type EAE and *Il17ra*<sup>-/-</sup> EAE dLN (day 12) were cultured in media or in presence of LPS, and glucose uptake measured via luciferase assay to detect

2-deoxyglucose-6-phosphate. Data pooled from 2 experiments, represented as mean  $\pm$  S.D. and each symbol represents an individual mouse; **D-F**: FRC were transfected in triplicate with  $I\kappa B\zeta$  siRNA for 24 hours then stimulated with IL-17 for 12 hours before analysis, **D**: *Nfkbiz* gene expression, **E**: *Fibronectin* gene expression **F**: Collagen 1a (*Col1a1*) gene expression, **G**: glucose-uptake competency assessed by flow cytometry of 2-NBDG added for final 30 minutes of culture, **H**: *Cpt1a* gene expression, all gene expression normalized to *Gapdh*. Data in (D-H) are representative of two independent experiments, represented as mean  $\pm$  S.D. and each symbol represents an individual mouse. P values calculated by one-way ANOVA, \* P<0.05, \*\* P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001.